Human PDE7B GenBank Accession No. NM_018945, (a.a. 109-end) with N-terminal GST-tag and C-terminal His-tag, MW=66 kDa, expressed in a Baculovirus infected Sf9 cell expression system.

Q9NP56

PDE7B, phosphodiesterase 7B

≥226 pmol/min/µg.

One unit is defined as the amount of enzyme that will convert 1 pmole of 3', 5'-cAMP to 5'-AMP per minute at 37°C.

Assayed using BPS's PDE7B kit, Cat. # 60371. Assay conditions: 10 mM Tris-HCl, pH 7.4, 10 mM MgCl₂, 0.05% Tween-20, 200 µM cAMP, 2.5 kU 5'-nucleotidase, and serial dilutions of PDE7B at 37°C for 20 min. Quantified by 5'-nucleotidase cleaving the 5'-AMP product and releasing the phosphate group which is detected by Malachite Green Reagent.

40 mM Tris-HCl, pH 8.0, 110 mM NaCl, 2.2 mM KCl, 3 mM DTT, 20% glycerol, and 16 mM glutathione

Aqueous buffer solution

>6 months at -80°C.

Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

1. Gardner,C., et al., Biochem. Biophys. Res. Commun. 272 (1), 186-192 (2000)
2. Sasaki,T., et al., Biochem. Biophys. Res. Commun. 271 (3), 575-583 (2000)

Application Reference(s):
1. Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders (2017)
2. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A (2015)

Avoid freeze/thaw cycles.

PDE

Recombinant Protein